1-4 of 4
Yoshiaki Kuroda, M.D.
Close
Sort by
Journal Articles

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Shoji Shimose, M.D., Akiro Kimura, M.D.
Journal: Blood
Blood (2007) 110 (11): 4780.
https://doi.org/10.1182/blood.V110.11.4780.4780
Published: 2007
Journal Articles

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Noelynn Oliver, Ph.D., Akiro Kimura, M.D.
Journal: Blood
Blood (2006) 108 (11): 5025.
https://doi.org/10.1182/blood.V108.11.5025.5025
Published: 2006
Journal Articles

What Is Important Factor of Bone Disease in Multiple Myeloma?.

Shoso Munemasa, M.D., Akira Sakai, M.D., Yoshiko Okikawa, M.D., Yoshiaki Kuroda, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Akiro Kimura, M.D.
Journal: Blood
Blood (2004) 104 (11): 4855.
https://doi.org/10.1182/blood.V104.11.4855.4855
Published: 2004
Journal Articles

The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma.

Yoshiaki Kuroda, M.D., Akira Sakai, M.D., Yoshiko Okikawa, M.D., Shoso Munemasa, M.D., Yuta Katayama, M.D., Yasuo Takimoto, M.D., Hajime Okita, M.D., Akiro Kimura, M.D.
Journal: Blood
Blood (2004) 104 (11): 5201.
https://doi.org/10.1182/blood.V104.11.5201.5201
Published: 2004